Correspondence to: Sandra M. Swain, M.D., Cancer Therapeutics Branch, National Naval Medical Center, 8901 Wisconsin Ave., Bldg. 8, Rm. 5101, Bethesda, MD 208895105 (e-mail: swains{at}mail.nih.gov).
The study by Li et al. (1) is prone to systematic bias. I agree with the authors' statement that their findings should not change current clinical practice. I disagree that their findings suggest that estrogen receptor-negative tumors may be more common. Instead, I would suggest that this is a hypothesis that needs to be tested.
REFERENCE
1
Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001;93:100813.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |